No travel needed: largest Home-Based study of myotonic dystrophy launches
NCT ID NCT07505342
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to understand why myotonic dystrophy type 1 affects people so differently. Researchers will remotely assess muscle strength, memory, and activity in 1,000 participants, and analyze their DNA from a blood sample. All activities are done from home using a mailed toolkit and video calls.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal why myotonic dystrophy affects people so differently and identify better ways to measure symptoms in daily life.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any therapy, and results may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2022
- Expected to finish
-
Jan 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Myotonic dystrophy DM1 between the ages of 18-88 years old
- Ages
-
18 to 88 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-88 years * Clinical diagnosis of DM1 * English speaking * Able to provide informed consent * Available wifi
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DM1 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Rochester
RECRUITINGRochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists hunt for biomarkers to unlock DM1 treatments
- Personalized exercise program aims to boost mobility in rare muscle diseases
- 700-Patient study seeks key clues to muscle disease
- New drug DYNE-101 aims to ease muscle symptoms in DM1
- New drug AOC 1001 tested for rare muscle disease
- Music therapy tested for rare muscle disease in kids